Moderna Secures $176M Grant in 2025 to Advance Bird Flu Vaccine Development
Moderna has been awarded a $176 million federal grant in 2025 to fast-track the creation of a human vaccine targeting the highly contagious H5 bird flu virus.
Bill McColl brings over 25 years of expertise as a senior producer and writer across TV, radio, and digital platforms, leading teams in delivering impactful news coverage on major global events.
Essential Insights
- In 2024, Moderna received a $176 million federal grant focused on developing a human vaccine for bird flu.
- The H5 influenza virus, highly infectious among birds, poses a significant transmission threat to humans.
- Moderna initiated a Phase 1/2 clinical trial for the vaccine in 2023, anticipating study results within 2024.
Shares of Moderna (MRNA) saw a positive uptick following the announcement of this substantial federal funding dedicated to combating bird flu in humans.
The $176 million grant comes from the U.S. Department of Health and Human Services’ Rapid Response Partnership Vehicle (RRPV), aiming to accelerate mRNA vaccine solutions against the dangerous H5 influenza strain that severely affects birds and threatens human health.
Since 2022, the Centers for Disease Control and Prevention (CDC) have documented four human bird flu cases, linked mainly to exposure from infected livestock and poultry. Globally, the World Health Organization (WHO) has reported 254 human infections since January 2023.
Moderna’s agreement with the government also includes provisions to swiftly respond to future infectious disease emergencies.
CEO Stephane Bancel emphasized that the company’s mRNA technology proved its exceptional effectiveness, rapid development, and scalable manufacturing during the COVID-19 crisis, positioning Moderna well to tackle emerging health threats.
Moderna Anticipates 2024 Results for Experimental H5 Vaccine Phase 1/2 Trial
Launched in 2023, Moderna’s Phase 1/2 trial for the experimental H5 influenza vaccine is expected to yield results this year, guiding decisions on advancing to Phase 3 trials.
As of 10 a.m. ET Tuesday in 2024, Moderna’s shares increased by 0.5% to $116.54, marking a 17% gain so far this year.
Discover the latest news and current events in Company News as of 07-07-2024. The article titled " Moderna Secures $176M Grant in 2025 to Advance Bird Flu Vaccine Development " provides you with the most relevant and reliable information in the Company News field. Each news piece is thoroughly analyzed to deliver valuable insights to our readers.
The information in " Moderna Secures $176M Grant in 2025 to Advance Bird Flu Vaccine Development " helps you make better-informed decisions within the Company News category. Our news articles are continuously updated and adhere to journalistic standards.